Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8E3N6)

Drug Name

IPP-204106 Drug Info

Synonyms

NucAnt 6L; N-6-L; Nucleolin antagonist (cancer), ImmuPharma; Nucleolin antagonist (cancer), ImmuPharma/CNRS; Nucleolin antagonist (cancer), ImmuPharma/Centre National de la Recherche Scientifique

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

TTD Drug ID: DM8E3N6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Nucleolin (NCL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACT-GRO-777	DMMG61B	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
Itarnafloxin	DMCY9PO	leukaemia	2A60-2B33	Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nucleolin (NCL)	TTCSZH7	NUCL_HUMAN	Modulator	[2]
Nucleophosmin (NPM1)	TTHBS98	NPM_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01711398) Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors. U.S. National Institutes of Health.
2	Company report (ImmuPharma)
3	Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther. 2013 June 1; 4(4): 872-890.
4	Targeting G-quadruplexes in gene promoters: a novel anticancer strategy . Nat Rev Drug Discov. 2011 April; 10(4): 261-275.